Department of Pathology, Shihezi University School of Medicine & the First Affiliated Hospital to Shihezi University School of Medicine, Shihezi, 832002, Xinjiang, China; Key Laboratory of Xinjiang Endemic and Ethnic Diseases (Ministry of Education), Shihezi University School of Medicine, North 2nd Road, Shihezi, 832002, Xinjiang, China.
The First Affiliated Hospital to Shihezi University School of Medicine, Shihezi, Xinjiang, China.
Pathol Res Pract. 2019 Oct;215(10):152612. doi: 10.1016/j.prp.2019.152612. Epub 2019 Aug 20.
Galectin-3 has an important function in the development of tumors. The purpose of this meta-analysis was to explore the relationships between the expression of galectin-3 on clinicopathological features and prognosis of colorectal cancer (CRC). A comprehensive literature search was used to identify eligible studies, and Stata software was conducted using in this meta-analysis. A total of 15 studies, including 1661 cases, were matched in the inclusion criteria. The pooled analysis indicated that galectin-3 expression was related to the poor overall survival (OS) in CRC patients (HR: 1.77, 95% CI: 1.36-2.31, P < 0.0001). Our meta-analysis also showed that cancerous tissues have higher levels of galectin-3 expression than normal tissues. Besides, positive galectin-3 expression was also related to advanced TNM stages(III/IV vs. I/II: OR 5.30, 95% CI: 2.42-11.61, P < 0.0001), higher Duke's stages (C/D vs. A/B: OR 4.00, 95% CI: 2.22-7.22, P < 0.0001), venous invasion (venous invasion vs. not: OR 3.02, 95%CI: 1.75-5.22, P < 0.0001) and higher CEA level (CEA≥5 ng/ml vs. ≤ 5 ng/ml: OR 2.09, 95% CI: 1.09-4.03, P = 0.03). In summary, our results indicated that overexpression of galectin-3 is significantly related to the tumor progression and could be a efficient in predicting the prognosis of patients with CRC.
半乳糖凝集素-3 在肿瘤的发展中具有重要作用。本荟萃分析的目的是探讨半乳糖凝集素-3 在结直肠癌（CRC）临床病理特征和预后中的表达关系。通过全面的文献检索确定了符合纳入标准的研究，并使用 Stata 软件进行了荟萃分析。共纳入 15 项研究，共 1661 例符合纳入标准。荟萃分析结果表明，半乳糖凝集素-3 表达与 CRC 患者总体生存（OS）不良相关（HR：1.77，95%CI：1.36-2.31，P < 0.0001）。我们的荟萃分析还表明，癌组织中半乳糖凝集素-3 的表达水平高于正常组织。此外，半乳糖凝集素-3 阳性表达与较晚的 TNM 分期（III/IV 期与 I/II 期：OR 5.30，95%CI：2.42-11.61，P < 0.0001）、较高的 Duke 分期（C/D 期与 A/B 期：OR 4.00，95%CI：2.22-7.22，P < 0.0001）、静脉侵犯（有静脉侵犯与无静脉侵犯：OR 3.02，95%CI：1.75-5.22，P < 0.0001）和较高的 CEA 水平（CEA≥5ng/ml 与≤5ng/ml：OR 2.09，95%CI：1.09-4.03，P = 0.03）显著相关。总之，我们的结果表明，半乳糖凝集素-3 的过表达与肿瘤进展显著相关，可作为预测 CRC 患者预后的有效指标。
